<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679702</url>
  </required_header>
  <id_info>
    <org_study_id>VI-ISRP-034</org_study_id>
    <nct_id>NCT03679702</nct_id>
  </id_info>
  <brief_title>A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome</brief_title>
  <acronym>VENUSSSS</acronym>
  <official_title>A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Krychman, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Viveve Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Center for Sexual Health and Survivorship Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to investigate non-surgical treatment for women who suffer from sexual
      complaints secondary to SSRI Sexuality Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>baseline to 6 month</time_frame>
    <description>safety of treatment of female sexual dysfunction secondary to SSRI sexuality syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>baseline to 3 and 6 months</time_frame>
    <description>Female Sexual Function Index total score (Minimum: 2.0) (Maximum: 36), Higher scores are better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve System</intervention_name>
    <description>Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently using SSRI for 3 months at a stable dose

        Exclusion Criteria:

          -  Pregnant, currently breastfeeding, or breast-fed within the last 6 months

          -  Has any implantable electrical device that could potentially be affected by use of
             radiofrequency.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Krychman</last_name>
    <phone>949-764-9300</phone>
    <email>mkrychman@icloud.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Center for Sexual Health and Survivorship Medicine</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Krychman, MD</last_name>
      <phone>949-764-9300</phone>
      <email>mkrychman@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Michael Krychman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Center for Sexual Health and Survivorship Medicine</investigator_affiliation>
    <investigator_full_name>Michael Krychman, MD</investigator_full_name>
    <investigator_title>Michael Krychman, MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

